×

收藏-健康网会员访问记录

网页标题:
×

注册健康网用户

用 户 名:
联 系 人:
性  别:
密  码:
重复密码:
电子邮箱:
邮箱验证码:
固定电话:
传  真:
手  机:
单位名称:
通信地址:
首选栏目:
×

找回密码

  • 1.选择找回方式
  • 2.确认验证信息
  • 3.修改密码
  • 4.修改成功
  • 找回方式:
  • 用 户 名:
  • 手机号码:

 您现在位置:健康网-医药产业 >> 研究报告 >> English reports >> English reports >> 浏览医药行业研究报告

Second line drugs for nonsmall-cell lung cancer report

作者:wangchun   来源:本站原创    点击数:0    更新时间:2007-8-31 14:41:16

[关键字]: nonsmall-cell lung cancer,Docetaxel,Gefitinib

健康网讯:

Market report of second line drugs for nonsmall-cell lung cancer (NSCLC) 

Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published:  June 2007
Format:  Adobe PDF
Price:  US$ 1,200
Contact: Mr. Bian chenghua   Ms. Wu huifang
Tel.: 86-10-68012929-2116/2101             Fax:  86-10-68052525
E-mail: bianch@healthoo.com   wuhf@healthoo.com   


Table of contents

1.Overview of Chinese anticancer market
2.Aanalysis on second line drugs for nonsmall-cell lung cancer
   Docetaxel
   Gefitinib
   Pemetrexed
Appendix: Reatail prices of the three drugs


Tables or figures

1 Sales values of second line drugs for nonsmall-cell lung cancer in sample hospitals from 2005 to 2006
2 Sales amount of second line drugs for nonsmall-cell lung cancer in sample hospitals from 2005 to 2006
3 Sales statistic of Docetaxel with different specifications from 2005 to 2006
4 Detail statistic of Docetaxel in sample hospitals in 2005
5 Detail statistic of Docetaxel in sample hospitals in 2006
6 Detail statistic of Gefitinib in sample hospitals from 2005 to 2006
7 Sales statistic of Pemetrexed in sample hospitals in 2006
8 Reatail prices of the three drugs

Second line drugs for nonsmall-cell lung cancer report
注册后,我们会为你提供报告样本并为您提供更全面的咨询服务
您的姓名  称谓: 先生女士
手机号码 
验证号码 
电子邮件 
单位名称 

服务热线

  • 联系项目:86-10-68012929-2103
  • 订购报告:86-10-68012929-2121
  • 邮件订购:leigy@healthoo.com